Patents by Inventor Vlad Edward Gregor

Vlad Edward Gregor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 9290503
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: January 15, 2014
    Date of Patent: March 22, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • Tyrosine kinase inhibitors
    Patent number: 9273055
    Abstract: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: March 1, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • Tyrosine kinase inhibitors
    Patent number: 9249147
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: February 2, 2016
    Assignee: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward Gregor
  • TYROSINE KINASE INHIBITORS
    Publication number: 20150038536
    Abstract: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.
    Type: Application
    Filed: June 18, 2014
    Publication date: February 5, 2015
    Inventor: Vlad Edward Gregor
  • NOVEL TYROSINE KINASE INHIBITORS
    Publication number: 20150011539
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Application
    Filed: July 3, 2014
    Publication date: January 8, 2015
    Inventor: Vlad Edward GREGOR
  • TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS
    Publication number: 20140228350
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Application
    Filed: January 15, 2014
    Publication date: August 14, 2014
    Applicant: CHEMBRIDGE CORPORATION
    Inventor: Vlad Edward GREGOR
  • Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Patent number: 8629147
    Abstract: The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: January 14, 2014
    Assignee: ChemBridge Corporation
    Inventors: Alexey Vyacheslavovich Anikin, Vidyasagar Reddy Gantla, Vlad Edward Gregor, Luyong Jiang, Yahua Liu, Danny Peter Claude McGee, Charles Chamchoumis Mikel, Jason Conrad Pickens, Thomas Roy Webb, Zheng Yan, Tong Zhu, Aleksander Kadushkin, Sergey Sviridov, Sergey Zozulya, Alexander Chucholowski, Douglas Eric McGrath
  • TRICYCLIC COMPOUND DERIVATIVES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY DISORDERS AND IMMUNOMODULATORY DISORDERS
    Publication number: 20120071473
    Abstract: Provided are compounds of the formula (I): or a stereoisomer, tautomer, salt, hydrate or prodrug thereof that modulate tyrosine kinase activity, compositions comprising the compounds and methods of their use.
    Type: Application
    Filed: September 23, 2011
    Publication date: March 22, 2012
    Inventors: Vlad Edward Gregor, Nelson Levy
  • TYROSINE KINASE INHIBITORS
    Publication number: 20120065233
    Abstract: The present disclosure relates to the field of tyrosine kinase enzyme inhibition, in particular anaplastic lymphoma kinase (ALK) inhibition using novel small molecules. Provided are compounds capable to modulate ALK activity, compositions that comprise the compounds, and methods of using the compounds for the treatment or prevention of diseases or conditions that are characterized by ALK activity or expression.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 15, 2012
    Inventors: Vlad Edward GREGOR, Nelson Levy
  • Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
    Publication number: 20080207635
    Abstract: The present invention provides compounds capable of modulating tyrosine kinases, compositions comprising the compounds and methods of their use.
    Type: Application
    Filed: November 2, 2006
    Publication date: August 28, 2008
    Inventors: Alexey Vyacheslavovich Anikin, Vidyasagar Reddy Gantla, Vlad Edward Gregor, Luyong Jiang, Yahua Liu, Danny Peter Claude McGee, Charles Chamchoumis Mikel, Jason Conrad Pickens, Thomas Roy Webb, Zheng Yan, Tong Zhu, Aleksander Kadushkin, Sergey Sviridov, Sergey Zozulya, Alexander Chucholowski, Douglas Eric McGrath
  • Neuropeptide-Y ligands
    Patent number: 6849733
    Abstract: There are disclosed novel neuropeptide Y ligands having the general formula I Wherein the symbols W, A, D, R1, R2, R3, R4 are further defined in the description. Compounds of formula I are agonists and antagonists of neuropeptide Y, and are therefore useful as regulators.
    Type: Grant
    Filed: August 22, 1997
    Date of Patent: February 1, 2005
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Yufeng Hong, Vlad Edward Gregor, Anthony Lai Ling, Eileen Valenzuela Tompkins
  • Non-peptide GnRH agents
    Patent number: 6646137
    Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and Z are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    Type: Grant
    Filed: November 22, 2000
    Date of Patent: November 11, 2003
    Inventors: Mark Brian Anderson, Alexander Polinsky, Yufeng Hong, Vlad Edward Gregor
  • Non-peptide antagonists of GLP-1 receptor and methods of use
    Patent number: 6469021
    Abstract: Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding to the GLP-1 receptor and/or prevent activation of the receptor by bound GLP-1. The invention further relates to a method of inhibiting the binding of GLP-1 to the GLP-1 receptor and a method of inhibiting the activation of the GLP-1 receptor. Intermediate compounds useful for making non-peptide GLP-1 receptor antagonists are also described.
    Type: Grant
    Filed: October 26, 2001
    Date of Patent: October 22, 2002
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Larry Kenneth Truesdale, Richard A. Bychowski, Javier Gonzalez, Atsuo Kuki, Ranjan Jagath Rajapakse, Min Teng, Dan Kiel, Daljit S. Dhanoa, Yufeng Hong, Tso-sheng Chou, Anthony L. Ling, Michael David Johnson, Vlad Edward Gregor
  • Non-peptide GnRH agents
    Patent number: 6218426
    Abstract: Non-peptide GnRH agents capable of inhibiting the effect of gonadotropin-releasing hormone are of the following general formula, where X1, X2, Y, and are defined variables: Such compounds and their pharmaceutically acceptable salts, multimers, prodrugs, and active metabolites are suitable for treating mammalian reproductive disorders and steroid hormone-dependent tumors as well as for regulating fertility, where suppression of gonadotropin release is indicated. Methods for synthesizing the compounds and intermediates useful in their preparation are also described.
    Type: Grant
    Filed: March 1, 1999
    Date of Patent: April 17, 2001
    Assignee: Agouron Pharmaceuticals, Inc.
    Inventors: Mark Brian Anderson, Alexander Polinsky, Yufeng Hong, Vlad Edward Gregor